New EU guideline on development of modified-release formulations
This article was originally published in Scrip
The European Medicines Agency has agreed a new guideline on the development of modified-release dosage forms, describing the studies that will be needed to demonstrate the efficacy, safety and pharmacokinetic properties of formulations such as prolonged, delayed and multiphasic-release formulations of medicines.
You may also be interested in...
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.
The team behind Sputnik V has attacked what it calls “fake news and provocations” in the EU as political arguments over the vaccine claim another ministerial scalp.
Once a major source of parallel exports because of its low drug prices, Italy is now taking steps to reduce medicine spending by targeting the burgeoning parallel import market.